| Literature DB >> 27160903 |
Pradeep Chaluvally-Raghavan1, Kang Jin Jeong2, Sunila Pradeep3, Andreia Machado Silva4, Shuangxing Yu2, Wenbin Liu5, Tyler Moss2, Cristian Rodriguez-Aguayo4, Dong Zhang2, Prahlad Ram2, Jinsong Liu6, Yiling Lu2, Gabriel Lopez-Berestein7, George A Calin7, Anil K Sood8, Gordon B Mills9.
Abstract
3q26.2 amplification in high-grade serous ovarian cancer leads to increased expression of mature microRNA miR551b-3p, which is associated with poor clinical outcome. Importantly, miR551b-3p contributes to resistance to apoptosis and increased survival and proliferation of cancer cells in vitro and in vivo. miR551b-3p upregulates STAT3 protein levels, and STAT3 is required for the effects of miR551b-3p on cell proliferation. Rather than decreasing levels of target mRNA as expected, we demonstrate that miR551b-3p binds a complementary sequence on the STAT3 promoter, recruiting RNA polymerase II and the TWIST1 transcription factor to activate STAT3 transcription, and thus directly upregulates STAT3 expression. Furthermore, anti-miR551b reduced STAT3 expression in ovarian cancer cells in vitro and in vivo and reduced ovarian cancer growth in vivo. Together, our data demonstrate a role for miR551b-3p in transcriptional activation. Thus, miR551b-3p represents a promising candidate biomarker and therapeutic target in ovarian cancer.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27160903 PMCID: PMC4914391 DOI: 10.1016/j.celrep.2016.04.034
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423